- Indivior
- 24 February 2025 09:05:01
Source: Sharecast
Indivior said the changes included a rapid initiation protocol and alternative injection sites, marking "a significant advancement" in the treatment of moderate to severe opioid use disorder.
The FTSE 250-listed firm stated healthcare providers can now initiate treatment with SUBLOCADE after a single dose of transmucosal buprenorphine and a one-hour observation period to confirm tolerability.
Indiviar also added that the drug can now be administered subcutaneously in the abdomen, thigh, buttock, or back of the upper arm, offering patients and healthcare providers increased flexibility in treatment administration.
"These label updates for SUBLOCADE underscore our dedication to evolving our treatment options to better serve individuals battling opioid use disorder," said chief scientific officer Dr Christian Heidbreder.
"These enhancements not only reflect our commitment to patient-centered care but also our ongoing efforts to align our treatments with real-world clinical needs, thereby potentially improving patient adherence and outcomes."
As of 0900 GMT, Indivior shares were down 0.073% at 688.0p.
Reporting by Iain Gilbert at Sharecast.com